P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression

Pluvio J. Coronado, Jose A. Vidart, Jose A. Lopez-asenjo, Maria Fasero, Vicente Furio-bacete, Javier Magrina, Manuel Escudero

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Objective: To investigate the prognostic value of p53 and HER-2/neu overexpression in endometrial cancer. Study Design: p53 and HER-2/neu immunostaining was performed in 114 paraffin-embedded specimens of endometrial cancer diagnosed and treated between 1990 and 1997. Nuclear p53 and membrane HER-2/neu immunostaining were used. Results: p53 and HER-2/neu overexpression was observed in 17 cases (14.9%) and in 19 cases (16.7%), respectively. In univariate analysis p53 (P < 0.001) and HER-2/neu (P = 0.018) overexpression had a positive correlation with a high risk of recurrence. In multivariate analysis, age (P < 0.001), FIGO stage (P < 0.001), differentiation (P = 0.013), non-endometrioid subtypes (P < 0.001) and p53 overexpression (P < 0.001), but not HER-2/neu overexpression, were independent prognostic indicators of recurrence. Simultaneous p53 and HER-2/neu overexpression made worse the prognostic (P < 0.001). Conclusions: p53 overexpression was an independent predictor of recurrent disease in endometrial cancer. HER-2/neu overexpression had a more limited effect but enhance the effect of p53.

Original languageEnglish (US)
Pages (from-to)103-108
Number of pages6
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Issue number1
StatePublished - 2001


  • Endometrial cancer
  • HER-2/neu
  • Immunohistochemistry
  • Prognostic factors
  • Survival
  • p53

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression'. Together they form a unique fingerprint.

Cite this